Nanopore assemblies and uses thereof

Through the functionalization of nanopore assemblies and probes formed by non-membrane proteins, the problem of insufficient sensitivity and specificity of existing biological nanopores when detecting analytes of different characteristics is solved, and high sensitivity and specificity for multiple analytes are achieved. Assay, suitable for single-molecular and high-throughput analysis.

CN118949941APending Publication Date: 2024-11-15OXFORD NANOPORE TECH LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410723966.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-02-12
Filing Date
2019-02-11
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing biological nanopores are insufficient in detecting analytes with different characteristics, and are difficult to use in versatile functions.

Method used

A nanopore assembly formed by multiple subunits, each of which contains a non-membrane protein, enables high sensitivity and specific detection of different analytes through protein engineering and functionalization of probes.

Benefits of technology

Provides a robust nanopore system suitable for detecting different analytes, capable of detecting analytes with different shapes, sizes and hydrophilic/hydrophobic properties at high sensitivity and specificity without labeling and amplification, suitable for single Molecular and high-throughput analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949941A_ABST
    Figure CN118949941A_ABST
Patent Text Reader

Abstract

The present disclosure provides a nanopore system assembled with a non-membrane protein for detecting an analyte. Methods, kits, and detection devices employing the disclosed nanopore systems are also disclosed. The nanopore system has a wide range of applications, including single molecule detection, DNA / RNA / peptide sequencing, sensing of chemicals, biological agents, and polymers, and disease diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention application is a divisional application based on an invention patent application with an application date of February 11, 2019, application number 201980020065.3 (international application number PCT / US2019 / 017432) and name “Nanopore components and their uses”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 629,604, filed on February 12, 2018, the disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0004] The present disclosure relates generally to nanopores, and more particularly to systems and methods for detecting analytes using nanopores assembled with non-membrane proteins. Background Art

[0005] Biological nanopores are protein channels embedded in a substrate, usually a lipid membrane. A variety of protein complexes in nature form ingenious channel-like structures, some of which have been explored as nanopores, including α-hemolysin, MspA, aerolysin, FluA, Omp F / G, CsgG, ClyA, and PA 63 For example, the bioprotein nanopore α-hemolysin (αHL) from Staphylococcus aureus has been used for single-molecule detection.

[0006] Recently, researchers have employed biological solid-state DNA origami and composite nanopores in single-molecule analysis. Biological nanopores have advantages over their synthetic counterparts, primarily because they can be reproducibly fabricated and modified with atomic-level precision that artificial nanopores cannot yet match. However, existing uses of biological nanopores also have disadvantages. For example, they are not versatile in providing different shapes, sizes, and hydrophilic / hydrophobic properties to detect different analytes with high sensitivity and specificity.

[0007] Therefore, there is still a great need for a robust nanopore system suitable for detecting analytes with different properties. Summary of the invention

[0008] The present disclosure satisfies this need in the art by providing a nanopore assembly for detecting an analyte. The nanopore assembly includes a channel formed by a plurality of subunits. Each of the subunits comprises a non-membrane protein capable of forming a protein channel. In some embodiments, each of the subunits comprises a polypeptide having a polypeptide sequence at least 75% identical to a polypeptide sequence selected from SEQ ID NOs: 1-35. In some embodiments, the polypeptide comprises a polypeptide sequence at least 75% identical to SEQ ID NOs: 4-12.

[0009] In some embodiments, the polypeptide may include at least one residue substituted with cysteine. In some embodiments, the polypeptide is derived from a phi29 portal protein or a tail protein. In some embodiments, the phi29 tail protein may include one or more of E595C, K321C, and K358C substitutions. In some embodiments, the phi29 tail protein may include one or more of K134I, D138L, D139L, D158L, E163V, E309V, D311V, K321V, K356A, K358A, D377A, D381V, N388L, R524I, R539A, and E595V substitutions.

[0010] In one aspect, the nanopore assembly further comprises a probe for detecting an analyte. The probe is operably connected to at least one subunit. The probe may be one of a chemical, a carbohydrate, an aptamer, a nucleic acid, a peptide, a protein, an antibody, and a receptor. In some embodiments, the probe comprises a sequence that is at least 75% identical to a sequence selected from SEQ ID NO: 36-79. In some embodiments, the probe is an anti-PSA antibody. The probe may be operably connected to at least one of the subunits via a covalent bond. The covalent bond comprises a disulfide bond, an ester bond, or a thiol bond. In some embodiments, the probe is operably connected to a position close to the entrance of the channel or to a position on the inner side of the channel.

[0011] The analyte can be one of nucleic acid, amino acid, peptide, protein, polymer and chemical molecule. In some embodiments, the analyte is one of PSA, CEA, AFP, VCAM, MiR-155, MiR-22, MiR-7, MiR-92a, MiR-122, MiR-192, MiR-223, MiR-26a, MiR-27a and MiR-802.

[0012] According to some embodiments of the nanopore assembly, the channel is embedded in a polymer vesicle. In some embodiments, the channel is inserted in a membrane. The membrane may include a polymer membrane or a lipid membrane. The polymer membrane may include an alternating copolymer, a periodic copolymer, a block copolymer, a diblock copolymer, a triblock copolymer, a terpolymer, or a combination thereof. In some embodiments, the polymer membrane comprises PMOXA-PDMS-PMOXA. In some embodiments, the nanopore assembly may also include cholesterol and / or porphyrin.

[0013] In another aspect, the present disclosure also provides a device for detecting an analyte. The device comprises the nanopore assembly described above and optionally a support for the nanopore assembly. The device may also comprise an electrode, to which the nanopore assembly is tethered.

[0014] In another aspect, the present disclosure also provides a kit comprising the nanopore assembly described above and optionally instructions for using the nanopore assembly.

[0015] In another aspect, the present disclosure provides a method for detecting an analyte. The method comprises: (1) contacting a sample containing the analyte with the nanopore assembly; (2) applying a current across a channel of the nanopore assembly; (3) determining the current passing through the channel at one or more time intervals; and (4) comparing the current measured at one or more time intervals with a reference current, wherein a change in the current relative to the reference current indicates the presence of the analyte in the sample. The analyte can be any of a nucleic acid, an amino acid, a peptide, a protein, a polymer, and a chemical molecule. In some embodiments, the reference current is measured using a sample that does not contain the analyte. In some embodiments, the nanopore assembly is placed on a support.

[0016] The foregoing overview is not intended to limit every aspect of the present disclosure, and other aspects are described in other parts, such as in the following detailed description. The entire document is intended to be associated as a unified disclosure, and it should be understood that all combinations of features described herein are considered, even if the combination of features is not found together in the same sentence or paragraph or part of the document. Other features and advantages of the present invention will become clear through the following detailed description. However, it should be understood that although the detailed description and specific examples indicate specific embodiments of the present disclosure, they are given only by way of illustration, because from this detailed description, various changes and modifications within the spirit and scope of the present disclosure will become clear to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figures 1A and 1B are schematic diagrams showing different functional layers of a typical non-membrane protein (shown as a truncated cone structure) used as a nanopore embedded in a polymer membrane. Figure 1A shows three different domains important for membrane anchoring. Figure 1B shows two regions that are particularly important for conjugation of functional modules for single-molecule sensing.

[0018] Figure 2 An example of mutagenesis in a membrane anchoring layer for direct membrane insertion is shown, with the phi29 gp9ΔLoop tail protein being shown as an example. The structure of the phi29 gp9ΔLoop tail protein channel before and after a series of hydrophobic mutations were made on the middle layer (framed) to increase its ability for direct membrane insertion. Exemplary mutation sites include: K134I, D138L, D139L, D158L, E163V, E309V, D311V, K321V, K356A, K358A, D377A, D381V, N388L, R524I, R539A, and E595V. After expression and purification, the mutant protein spontaneously inserts into the polymer membrane. Representative positively charged residues (e.g., R and K) and representative negatively charged residues (e.g., E, Q, D, and N) are indicated.

[0019] Figure 3 An example of phage protein expression and purification is shown, where protein expression and purification of the phi29 gp9 tail protein is shown. Coomassie blue stained SDS-PAGE gel shows expression of the phi29 gp-9 tail protein channel with a molecular weight of 70.33 kDa.

[0020] Figure 4 is an exemplary Coomassie blue-stained SDS-PAGE gel showing that the majority of the gp-9 tail protein channel is present in the 100 kDa column after purification and assembly, indicating that the channel is assembled from its approximately 70 kDa monomeric units.

[0021] Figure 5 An example of target site selection in a non-membrane protein surface is shown using the phi29 gp9 tail protein. The phi29 gp9 tail protein structure shows three possible residues for mutagenesis to cysteines for conjugation of a hydrophobic membrane anchoring module.

[0022] Figure 6 Examples of non-membrane protein channels inserted into polymer membranes are shown, as demonstrated using the phi29 gp9ΔLoop tail protein. Single channel recording data showing that the phi29 gp9ΔLoop channel inserts directly into the composite PMOXA6-PDMS 65-PMOXA6 polymer film. Conductive buffer: 1M NaCl, 5mM Tris, pH 7.6. Applied voltage: 75mV.

[0023] FIG. 7A and FIG. 7B show the structures of the full-length gp1 portal protein of bacteriophage P22 ( FIG. 7A ) and a barrel deletion mutant ( FIG. 7B ).

[0024] Figure 8 An example of target site selection for membrane anchoring in a non-membrane protein is shown, as demonstrated using the P22 gp1 portal protein. A representative conjugation site (e.g., an accessible cysteine ​​residue, C283) for incorporation into a membrane anchoring domain is shown on the structure of the bacteriophage P22 gp1 portal protein.

[0025] Fig. 9 Examples of non-membrane protein pores functionalized with fused peptide probes are shown, as demonstrated using the P22 gp1 portal protein fused to VCAM1. Coomassie blue stained gel showing purified bacteriophage P22 gp1 portal protein full length and barrel structure deletion mutants fused to the VCAM1 probe at the C-terminus.

[0026] Fig.10 Examples of non-membrane protein pores functionalized with fused peptide probes are shown, as demonstrated using the P22 gp1 portal protein fused to PSA. Coomassie blue stained gel showing purified bacteriophage P22 gp1 portal protein barrel deletion mutant fused to the PSA probe at the C-terminus.

[0027] Fig.11 An example of a non-membrane protein pore functionalized with a fused peptide probe for single molecule sensing is shown, as demonstrated using a P22 gp1 portal protein fused to a PSA probe for detection of PSA. Single channel recording data show that the P22 gp1 protein channel carrying the fused PSA probe is directly inserted into a polymer membrane of the composition PMOXA6-PDMS35-PMOXA6. In the presence of PSA (10 ng / uL), the probe binds to PSA and results in a characteristic current blocking event. Conductive buffer: 1 M KCl, 5 mM Tris, pH 7.6. Applied voltage: 75 mV.

[0028] Fig.12 Examples of target site selection for membrane anchoring in non-membrane proteins are shown, as demonstrated using the T4 gp20 portal protein. Representative conjugation sites for incorporation into membrane anchoring domains are indicated on the structure of the bacteriophage T4 gp20 portal protein (e.g., via accessible cysteine ​​residues C217, 245, 246).

[0029] Fig.13An example of labeling of non-membrane protein channels with cholesterol-PEG-maleimide for membrane anchoring is shown, as demonstrated using the T4 gp20 portal protein.

[0030] Fig.14 An example of a non-membrane protein channel inserted in a polymer membrane is shown, as demonstrated using the cholesterol-carrying T4gp20 portal protein. Stepwise direct insertion of the protein was observed under an applied potential. Conductive buffer: 1M KCl, 5mM Tris, pH 7.6. Applied voltage: 100mV. Membrane: PMOXA6-PDMS35-PMOXA6.

[0031] Fig.15 An example of conjugation of probes to non-membrane protein channels via click chemistry is shown, as demonstrated using the phi29 gp10 portal protein. The thiol-miR-21 probe was labeled with TCO (trans-cyclooctene), followed by conjugation of the TCO-miR-21 probe to methyltetrazine protein. SDS-PAGE gels verified the binding of target miR-21 to the miR-21 probe conjugated to the protein.

[0032] Fig.16 An example of analyte (e.g., miRNA) detection using a probe-functionalized non-membrane protein pore is shown, as demonstrated using the T4 gp20 portal protein. In the presence of the target miRNA, a current blockade event is observed, indicating that the miRNA is detected at the single molecule level. Conductive buffer: 1M KCl, 5mM Tris, pH 7.6. Applied voltage: 100mV. Membrane: PMOXA6-PDM S35-PMOXA6.

[0033] Fig.17A An example of a polyoxazoline-based triblock copolymer for the insertion of a non-membrane protein as a nanopore is shown, such as using PMOXA6-PDMS 65 -PMOXA6 shown.

[0034] Fig. 17B The stability of the flat membrane over the course of 2 days is shown. The membrane showed no signs of membrane leakage. Membrane: PMOXA6-PDMS 35 -PMOXA6.

[0035] Fig. 17C and Fig.17D Examples of the use of polymersomes fused to planar polymer membranes to insert into non-membrane protein pores, such as using the phi29 gp9 tail protein ( Fig. 17C ) and P22 gp1 portal protein ( Fig.17D ) is displayed. Fig. 17C Planar membrane and polymersome composition in: PMOXA11 -PDMS 65 -PMOXA 11 ; Fig.17D Planar membrane and polymersome composition in PMOXA5-PDMS 13 -PM OXA5;

[0036] Fig.18 An example of a non-membrane protein with a Spytag / Spycatcher system for incorporating an analyte probe is shown, as demonstrated using the phi29 gp10 portal protein. A Coomassie blue-stained SDS-PAGE gel shows that the Spytag incorporated into the phi29 gp10 portal protein binds to the PSA-Spycatcher protein to form a complex. The functionalized pore can then be used to sense PSA, as Fig.19 shown.

[0037] Fig.19 An example of a non-membrane protein channel for analyte detection using the spytag-spycatcher system is shown, as demonstrated using the phi29 gp10 portal protein. Directly following insertion, the spytag / spycatcher (PSA probe) on the phi29 gp10 portal is able to detect PSA (10 ng / uL) in solution, as shown as a current blockade event. Conductive buffer: 1 M KCl, 5 mM Tris, pH 7.6. Applied voltage: 100 mV. Membrane: PMOXA6-PDMS 35 -PMOXA6. DETAILED DESCRIPTION

[0038] The present disclosure provides a robust nanopore system and method suitable for detecting different analytes. It allows detection of single molecules and target molecules present with other contaminants. The system provides label-free, amplification-free real-time detection. It requires very low sample amounts and can be used for high-throughput analysis. The system can be suitable for detecting various analytes (e.g., small molecules, polymers, polypeptides, and nucleotides) with different shapes, sizes, and hydrophilic / hydrophobic properties with high sensitivity and specificity.

[0039] The present disclosure satisfies the needs of the art by providing nanopores formed by non-membrane proteins (e.g., proteins derived from bacteriophages). In order to generate the disclosed nanopores, bacteriophage proteins are expressed, purified, self-assembled, and inserted into lipid membranes or polymer membranes. However, non-membrane protein channels are more difficult to insert directly into lipid bilayers or polymer membranes. Unlike membrane protein channels, non-membrane protein channels usually lack hydrophobic layers in the middle and hydrophilic layers at both ends. The present invention overcomes this limitation by adopting a series of methods, which are used to insert various protein channels into polymer membranes directly or through efficient fusion mechanisms. In addition, in some cases, protein engineering, such as site-directed mutagenesis, insertion and deletion of amino acids, and the introduction of functional modules are performed to tune the nanopore characteristics to meet different detection needs.

[0040] The disclosed nanopore system has a wide range of applications, including but not limited to single molecule detection, DNA / RNA / peptide sequencing, sensing of chemicals, biological agents and polymers, and disease diagnosis. As will be further described below, methods, kits and detection devices using the disclosed nanopore system are also within the scope of the present disclosure.

[0041] I. Nanopore Assembly

[0042] One aspect of the present disclosure relates to nanopores formed by non-membrane proteins. Non-membrane proteins suitable for forming nanopores can be derived from cellular DNA translocases, helicases, terminases, ATPases and fragments thereof. Non-membrane proteins suitable for forming nanopores can also include proteins involved in DNA repair, replication, recombination, chromosome segregation, DNA / RNA transport, membrane sorting, cell recombination, cell division, bacterial binary fission and other processes.

[0043] The nanopore may include multiple subunits, each of which includes a non-membrane protein. For example, the nanopore may include 10 to 15 subunits of a phage portal protein or 5 to 10 subunits of a phage tail protein. The non-membrane protein channel forming the nanopore may be derived from a phage portal protein, including but not limited to T3, T4, T5, T7, SPP1, P22, P2, P3, λ, μ, HK97, and C1. For example, the non-membrane protein channel forming the nanopore may be derived from a phage tail protein, including but not limited to phi29, C1, Neisseria meningitidis serogroup B, T4, phiX174, λ, SPP1, T5, μ, F4-1, P2, Serratia phage KSP90, Enterobacteriaceae phage T7M, phage HK97.

[0044] Variants and homologs with significant identity to bacteriophage proteins (e.g., phage portal or tail proteins) are also within the scope of the present disclosure, including but not limited to T3, T4, T5, T7, SPP1, P22, P2, P3, λ, μ, HK97, and C1. For example, such variants and homologs can have a sequence having at least about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity to the sequence of the bacteriophage portal protein described herein.

[0045] Biological pore mutagenesis can be used to optimize protein pores for assembly or use in the compositions or methods described herein. For example, protein engineering and mutagenesis techniques can be used to mutate biological pores and adjust their properties for specific applications. Thus, the nanopore assembly can include a channel formed by a plurality of subunits. Each of the subunits comprises a polypeptide having a polypeptide sequence having at least 75% identity with a polypeptide sequence selected from SEQ ID NO: 1-35. In some embodiments, the polypeptide comprises a polypeptide sequence at least 75% identical to SEQ ID NO: 4-12.

[0046] The subunit may comprise one or more substitutions, deletions or insertions to facilitate functionalization of the nanopore or insertion into the membrane. For example, the subunit may comprise at least one residue substituted with cysteine ​​so that a functional group may be attached to the subunit via a disulfide bond. For example, a cysteine ​​residue may be used to conjugate a chemical such as a porphyrin to the nanopore. In some embodiments, the subunit may comprise a phi29gp9 protein having one or more of the substitutions E595C, K321C, and K358C.

[0047] In addition, the subunit may include a phi29 gp9 protein having one or more of K134I, D138L, D139L, D158L, E163V, E309V, D311V, K321V, K356A, K358A, D377A, D381V, N388L, R524I, R539A, and E595V substitutions. Substitution of charged residues (e.g., K, R, D, E) with hydrophobic residues (e.g., A, V, L) increases the hydrophobicity of the protein locally and globally.

[0048] In some embodiments, the process of incorporating protein channels into membranes or nanodiscs can benefit from affinity tags on the protein (e.g., polyhistidine affinity tags) and from purification of mixed nanopore populations on affinity columns (e.g., Ni columns). Affinity tags and chemical conjugation techniques (e.g., modification of cysteine ​​as described above) can be used to attach tethers to nanopores for use in various methods, compositions, or devices described herein. For example, the resulting tethers can be used to attract or attach nanopores to solid supports or electrodes.

[0049] Table 1. Amino acid sequences of channel proteins

[0050]

[0051]

[0052]

[0053]

[0054]

[0055]

[0056]

[0057]

[0058]

[0059] Table 2. Sequences of adapters and probes

[0060]

[0061]

[0062]

[0063] Table 3. Nucleotide sequences

[0064]

[0065]

[0066]

[0067]

[0068]

[0069]

[0070]

[0071]

[0072]

[0073]

[0074]

[0075]

[0076]

[0077]

[0078]

[0079] As used herein, the term polypeptide "variant" is a polypeptide that generally differs from the polypeptides explicitly disclosed herein by one or more substitutions, deletions, additions and / or insertions. Such variants may be naturally occurring or may be synthetically produced, for example, by modifying one or more of the above polypeptide sequences of the disclosure, and evaluating one or more biological activities of the polypeptides as described herein, and / or using any of a number of techniques well known in the art.

[0080] For example, certain amino acids can be substituted for other amino acids in a protein structure without significantly losing the ability of the protein to bind to other polypeptides or cells. Since it is the binding ability and properties of a protein that determine the biological functional activity of a protein, certain amino acid sequence substitutions can be made in the protein sequence and therefore in its underlying DNA coding sequence to obtain a protein with similar properties. Therefore, it is contemplated that various changes can be made in the peptide sequences of the disclosed compositions or the corresponding DNA sequences encoding the peptides without significantly losing their biological utility or activity.

[0081] Variant sequences include those in which conservative substitutions have been introduced by modifying the polynucleotides encoding the polypeptides of the present disclosure. Amino acids can be classified according to physical properties and contributions to secondary and tertiary protein structures. Such conservative modifications include amino acid substitutions, additions and deletions. Conservative amino acid substitutions are amino acid substitutions in which amino acid residues are replaced by amino acid residues with similar side chains. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with the following side chains: basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0082] "Sequence identity" or "homology" refers to the percentage of residues in a polynucleotide or polypeptide sequence variant that are identical to the non-variant sequence, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum homology percentage. In specific embodiments, polynucleotide and polypeptide variants have at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% homology to a polynucleotide or polypeptide described herein.

[0083] The polypeptide variant sequence may share 70% or more (i.e., 80%, 85%, 90%, 95%, 97%, 98%, 99% or more) sequence identity with the sequences listed in the disclosure. Polypeptide variants may also include polypeptide fragments comprising continuous stretches of various lengths of the amino acid sequences disclosed herein. Polypeptide variant sequences include at least about 5, 10, 15, 20, 30, 40, 50, 75, 100, 150 or more continuous peptides of one or more sequences disclosed herein and all intermediate lengths therebetween.

[0084] II. Nanopore Assembly Functionalized with Probes

[0085] On the one hand, the nanopore assembly also includes a probe for detecting an analyte. The probe is operably connected to at least one subunit. This probe is conjugated to the nanopore assembly to allow selective binding of one or more analytes. The probe can be conjugated to the nanopore assembly with various stoichiometrics (molar ratio between the probe and the nanopore assembly). In one example, the probe can be conjugated to each subunit. In another example, only one probe is conjugated to the nanopore assembly. It is also envisioned that the nanopore assembly includes two or more different types of probes. Such functionalized nanopore assemblies can be used to detect analytes, such as nucleic acids, amino acids, peptides, proteins, polymers and chemical molecules. In some embodiments, the analyte is one of PSA, CEA, AFP, VCAM, MiR-155, MiR-22, MiR-7, MiR-92a, MiR-122, MiR-192, MiR-223, MiR-26a, MiR-27a, MiR-802 or a fragment thereof.

[0086] The terms "specific binding", "selective binding", "selectively binds", and "specifically binds" refer to the ability of a probe on a nanopore assembly to bind more strongly to an analyte in a sample than to other contaminants present in the sample. For example, in a binding assay such as ELISA, equilibrium dialysis, or The probe can be detected with a surface plasmon resonance (SPR) technique in a 2000 surface plasmon resonance instrument at a speed of approximately less than 10 -6 M, such as approximately less than 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or even lower equilibrium dissociation constant (Kd) binds to the analyte.

[0087] The probe can be one of a chemical, a carbohydrate, an aptamer, a nucleic acid, a peptide, a protein, an antibody, and a receptor. In some embodiments, the probe may comprise a sequence that is at least 75% identical to the sequence of SEQ ID NO: 36-79. In some embodiments, the probe is an anti-PSA antibody. The probe is operably connected to at least one subunit via a covalent bond. The probe can be connected to the subunit via one or more functional sites on the subunit. Such functional sites can be introduced by mutagenesis, such as substitution with cysteine ​​or other non-natural amino acids. The probe can also be connected to the channel via recognized chemical methods, including but not limited to ester bonds, click chemistry, and sulfhydryl bonds. In some embodiments, the probe is operably connected to a position close to the entrance of the channel or at a position on the inner side of the channel.

[0088] III. Nanopore Assemblies with Membranes

[0089] On the other hand, the present disclosure provides a nanopore assembly in which a channel is inserted in a membrane. Depending on the application, the polymer membrane can have various compositions, in a stand-alone form or in a microfluidic device. The polymer membrane embedded channel exhibits robust electrophysiological properties, which is the primary feature of single-molecule analysis based on nanopores. The membrane can include a polymer membrane (e.g., a planar polymer membrane) or a lipid membrane. The properties of the polymer membrane can be symmetrical or asymmetrical. For example, the polymer membrane is an alternating copolymer (e.g., ABAB-...) or a periodic copolymer (e.g., AA-BB-AA-BB...). In another example, the polymer membrane can be a block copolymer consisting of two or more homopolymer subunits connected by covalent bonds. Alternatively, the polymer membrane can be a diblock or triblock copolymer (e.g., PMOXA-PDMS-PMOXA). The polymer membrane can also be a terpolymer consisting of three different monomers.

[0090] In some embodiments, the polymer film comprises an alternating copolymer, a periodic copolymer, a block copolymer, a diblock copolymer, a triblock copolymer, a terpolymer, or a combination thereof. In some embodiments, the polymer film comprises PMOXA-PDMS-PMOXA.

[0091] In some embodiments, channel is embedded in polymer vesicle of various sizes.In some embodiments, polymer vesicle is merged with planar polymer film to insert channel.Polymer vesicle is made up of hydrophilic-hydrophobic block copolymer, is arranged with double-layer vesicle system with central aqueous core.They have hydrophilic inner core and lipophilic double layer.The difference between them and nano particle is that they contain hydrophilic core, rather than the lipophilic core in the case of nano particle.Although they have double-layer structure, due to the presence of thick and rigid double layer, they have higher stability than liposome.They contain the hydrophilic core that provides protein affinity environment.

[0092] In some embodiments, the channel is inserted into a polymer membrane in the presence of any detergent of various compositions (e.g., DDM, DOC, Tween, SDS, and Brij-based detergents). In some embodiments, the protein channel is reconstituted into polymer vesicles in the presence of varying amounts of glycerol, CsCl, and / or sucrose for efficient fusion.

[0093] In some embodiments, by mutagenesis (for example, containing one to several substitutions), protein channel is reengineered to facilitate insertion in (plane) polymer film. In addition, for the purpose of insertion in polymer film, protein channel is reengineered to introduce functional sites for site-specific labeling with chemicals or biopolymers. Such functional sites include cysteine ​​residues for conjugating chemicals (such as porphyrins) or biomolecules (such as cholesterol or any hydrophobic lipid modules or nucleic acids of various lengths). Functional sites / groups can also include non-natural amino acids and connections produced by recognized chemical methods, including but not limited to esters, click chemistry and sulfhydryls.

[0094] In some embodiments, the location of conjugation is in the membrane anchoring layer of the channel, such as residues 70-80, 110-140, 155-245, 300-340, 410-435 of the T4 gp 20 portal protein; residues 10-45, 250-300 of the P22 gp1 portal protein; and residues 130-170, 300-325, 350-390, 530-595 of the phi29 gp9 tail protein. Thus, to increase or decrease the hydrophobicity of the ribbon region for membrane insertion purposes, reengineering can include mutagenesis (e.g., substitution, insertion, deletion) of any of the following: residues 70-80, 110-140, 155-245, 300-340, 410-435 of the T4 gp 20 portal protein; residues 450-500, 350-380 of the P22 gp1 portal protein; and residues 130-170, 300-325, 350-390, 530-595 of the phi29 gp9 tail protein.

[0095] In some embodiments, the position of conjugation is in the cis and trans hydrophilic layers of the channel, such as residues 465-515, 285-305 of the T4 gp 20 portal protein; residues 450-500, 350-380 of the P22 gp1 portal protein; and residues 20-50 and 250-300 of the phi29 gp9 tail protein. Thus, to increase or decrease the hydrophobicity of the ribbon region for membrane insertion purposes, reengineering can include mutagenesis (e.g., substitution, insertion, deletion), which can include any of the following: residues 465-515, 285-305 of the T4 gp 20 portal protein; residues 450-500, 350-380 of the P22 gp1 portal protein; and residues 20-50 and 250-300 of the phi29 gp9 tail protein.

[0096] IV. Devices and Kits Comprising Nanopore Assemblies

[0097] In another aspect, the present disclosure also provides a kit and a detection device for detecting an analyte. The kit may include the nanopore assembly, optionally a buffer, and optionally instructions for using the nanopore assembly.

[0098] The device may include the nanopore assembly and a support for the nanopore assembly. The detection device may also include electrodes embedded in a solid support. The electrodes may be used to monitor the assembly of the protein nanopore into the membrane. The electrodes may also be used for data acquisition during the analyte detection step. The electrodes for monitoring and detection need not be embedded in a support and may, for example, be arranged in a separate application specific integrated circuit (ASIC) chip.

[0099] As used herein, the term "support" refers to a rigid substrate that is insoluble in aqueous liquids and that does not allow liquids to pass through it without an orifice. Exemplary solid supports include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylic resins, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, Teflon, TM , cyclic olefins, polyimides, etc.), nylon, ceramics, resins, Zeonor, silica or silica-based materials (including silicon and modified silicon), carbon, metals, inorganic glasses, fiber bundles, and polymers. Particularly useful supports include modified silicon, such as SiN membranes on Si substrates. For some embodiments, the support is located within a flow cell device or other container.

[0100] In some embodiments, the nanopores are fabricated on a substrate such as a chip, disk, block, plate, etc. Such substrates can be made of various materials including, but not limited to, silicon, glass, ceramics, germanium, polymers (e.g., polystyrene), and / or gallium arsenide. The substrate may or may not be etched, for example, the chip may be a semiconductor chip.

[0101] In specific embodiments, the detection device may include a reservoir in contact with the nanopore array. The reservoir may contain electrodes positioned to apply an electric current across the pores formed by the protein nanopores.

[0102] In some embodiments, a detection device of the present disclosure may include (a) an electrode; (b) a nanopore tethered to the electrode; and (c) a membrane surrounding the nanopore. Multiple embodiments are also provided. For example, a detection device may include (a) a plurality of electrodes; (b) a plurality of nanopores, each of the nanopores tethered to one of the plurality of electrodes; and (c) a membrane surrounding each of the nanopores.

[0103] The nanopore can be tethered to an electrode (e.g., via an insulating pad) using a covalent moiety or a non-covalent binding moiety. An example of a covalent attachment is when a nucleic acid tether is covalently attached to the nanopore and covalently attached to an insulating pad. Other tethers can be similarly used for covalent attachment, including, for example, non-nucleic acid tethers, such as polyethylene glycol or other synthetic polymers. An example of a non-covalent attachment is when the nanopore has an affinity moiety attached, such as a polyhistidine tag, a Strep-tag, or other amino acid-encoded affinity moiety. The affinity moiety can be non-covalently attached to a ligand on an insulating pad, such as nickel or other divalent cations that bind polyhistidine, or biotin (or its analogue) that binds a Strep-tag. In some embodiments, it is not necessary to use such an amino acid affinity moiety.

[0104] As described herein, the nanopore (whether a composite nanopore or a tethered nanopore) can be coupled to a detection circuit to record the electrical signal in the methods of the present disclosure, the detection circuit including, for example, a patch clamp circuit, a tunneling electrode circuit, or a lateral conductance measurement circuit (such as a graphene nanoribbon, or a graphene nanogap). In addition, the hole can also be coupled to an optical sensor that detects a label on the polynucleotide, such as a fluorescent moiety or a Raman signal generating moiety.

[0105] The detection devices of the present disclosure can be used to detect any of a variety of analytes, including but not limited to ions, nucleic acids, nucleotides, polypeptides, biologically active small molecules, lipids, sugars, etc. Therefore, in the devices shown herein, one or more of these analytes can be present in the orifice of the protein nanopore or pass through the orifice of the protein nanopore.

[0106] Other detection techniques that can be applied to the devices shown herein include, but are not limited to, detection events, such as the movement of a molecule or a portion of this molecule, particularly in the case where the molecule is DNA or an enzyme such as a polymerase that binds DNA. For example, Olsen et al., JACS 135: 7855-7860 (2013), incorporated herein by reference, discloses the conjugation of a single molecule of the Klenow fragment (KF) of DNA polymerase I into an electronic nanocircuit to allow electronic recording of enzyme function and dynamic variability, and to resolve separate nucleotide incorporation events. Alternatively, for example, Hurt et al., incorporated herein by reference, JACS 131: 3772-3778 (2009) discloses measuring the residence time of a complex of DNA and KF on top of a nanopore in an applied electric field. Alternatively, for example, Kim et al., Sens. Actuators B Chem. 177: 1075-1082 (2012), incorporated herein by reference, discloses the use of an amperometric sensor in an experiment involving DNA captured in an α-hemolysin nanopore. Alternatively, for example, Garalde et al., J. Biol. Chem. 286: 14480-14492 (2011), incorporated herein by reference, discloses differentiation of KF-DNA complexes based on their properties when trapped in an electric field atop an α-hemolysin pore. Other references disclosing measurements involving α-hemolysin include the following (all to Howorka et al., incorporated herein by reference): PNAS 98: 12996-13301 (2001); Biophysical Journal 83: 3202-3210 (2002); and Nature Biotechnology 19: 636-639 (2001).

[0107] In some embodiments, the present invention relates to channel proteins assembled into lipid bilayer membranes. The presence of analytes is monitored by ionic currents passing through the pores at a fixed applied potential, wherein the interruption of the current indicates the interaction of the analyte with the channel protein. In some embodiments, the stabilized sensor chip contains a single protein nanopore protein. The protein nanopore sensor chip can be applied to measurements performed at the single molecule level, i.e., stochastic sensing. By monitoring the ionic currents passing through the pores at a fixed applied potential, various analytes can be distinguished based on the amplitude and duration of individual current blocking events. V. Methods for Detecting Analytes Using Nanopore Assemblies

[0108] In another aspect, the present disclosure provides a method for detecting / sensing an analyte. The method comprises: (1) contacting a sample containing the analyte with the nanopore assembly; (2) applying a current across a channel of the nanopore assembly; (3) determining the current passing through the channel at one or more time intervals; and (4) comparing the current measured at the one or more time intervals with a reference current, wherein a change in the current relative to the reference current indicates the presence of the analyte in the sample. In some embodiments, the reference current is measured using a sample that does not contain the analyte. In some embodiments, the nanopore assembly is placed on a support.

[0109] In some embodiments, the method may include measuring the ionic current and / or the change in the current characteristic induced by the translocation of each unit of analyte or polymer through the channel. In some embodiments, the method may include measuring the ionic current and / or the change in the current characteristic induced by the transient or permanent binding of each unit of analyte or polymer to a probe coupled to the channel, the binding causing the change in the current characteristic.

[0110] The analyte that can be detected by the method disclosed in the present disclosure can be any one of nucleic acids, amino acids, peptides, proteins, polymers and chemical molecules. The nucleic acid detected in the method can be single-stranded, double-stranded or contain both single-stranded and double-stranded sequences. Nucleic acid molecules can originate from double-stranded forms (e.g., dsDNA) and can be optionally converted into single-stranded forms. Nucleic acid molecules can also originate from single-stranded forms (e.g., ssDNA, ssRNA), and ssDNA can be optionally converted into double-stranded forms.

[0111] VI. Definitions

[0112] To aid in understanding the detailed description of compositions and methods according to the present disclosure, some specific definitions are provided to facilitate unambiguous disclosure of various aspects of the present disclosure.

[0113] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0114] It should be noted that, as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Unless otherwise stated, the terms "including", "comprising", "containing", or "having" and variations thereof are intended to encompass the items listed thereafter and equivalents thereof as well as additional subject matter.

[0115] As used herein, when used with respect to a collection of items, the term "each" is intended to identify an individual item in the collection, but does not necessarily refer to every item in the collection. Exceptions may occur if explicit disclosure text or context clearly indicates otherwise.

[0116] Unless otherwise stated, the use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the invention and does not impose any limitation on the scope of the invention. No language in the specification should be construed as indicating any non-claimed element is essential to the practice of the invention.

[0117] As used herein, the terms "nanopore" and "channel" are used to refer to a structure having a nanoscale passage through which an ionic current can flow. The inner diameter of a nanopore can vary greatly depending on the intended use of the device. Typically, a channel or nanopore has an inner diameter of at least about 0.5 nm, typically at least about 1 nm, and more typically at least about 1.5 nm, wherein the diameter may be as long as 50 nm or more, but in many embodiments, will not exceed about 10 nm, and typically will not exceed about 2 nm.

[0118] As used herein, the term "analyte" refers to a substance or chemical component that is being analyzed or is intended to be detected. It is contemplated that the present invention is not limited to a particular analyte. Representative analytes include ions, sugars, proteins, nucleic acids, and nucleic acid sequences.

[0119] As used herein, the term "membrane" refers to a sheet or other barrier that prevents the passage of an electric current or fluid. Compared to the solid supports shown herein, membranes are generally flexible or compressible. The membrane can be made of a lipid material, for example, to form a lipid bilayer, or the membrane can be made of a non-lipid material. The membrane can be in the form of a copolymer membrane, for example, formed by a diblock polymer or a triblock polymer, or in the form of a monolayer, for example, formed by a bolalipid. See, for example, Rakhmatullina et al., Langmuir: the ACS Journal of Surfaces and Colloids 24: 6254-6261 (2008), which is incorporated herein by reference.

[0120] As used herein, the term "lipid membrane" means a membrane made primarily of compounds containing saturated or unsaturated, branched or unbranched, aromatic or non-aromatic hydrocarbon groups. The membrane can be composed of a variety of lipids. Examples of lipids include, but are not limited to, fatty acids, mono-, di- and triglycerides, glycerophospholipids, sphingolipids, steroids, lipoproteins and glycolipids.

[0121] "Nucleic acid" or "nucleic acid sequence" or "nucleic acid molecule" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. The term nucleic acid is used interchangeably with gene, complementary DNA (cDNA), messenger RNA (mRNA), oligonucleotides and polynucleotides. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties to the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotide. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral methylphosphonates, 2-O-methyl ribonucleotides, peptide nucleic acids (PNAs). The term encompasses molecules formed from any known base analogs of DNA and RNA such as, but not limited to, 4-acetylcytosine, 8-hydroxy-N6-methyladenine, aziridinyl-cytosine, pseudoisocytosine, 5-(carboxyhydroxymethyl)uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxy-methylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5- Methylaminomethyluracil, 5-methoxyamino-methyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarbonyl-methyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetate methyl ester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetate methyl ester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine and 2,6-diaminopurine.

[0122] Unless otherwise indicated, a particular nucleic acid sequence also implies that conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as explicitly indicated sequences are encompassed. Specifically, in some aspects, degenerate codon substitutions are achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed bases and / or deoxyinosine residues (Batzer, Nucleic Acid Res. 19: 5081, 1991; Ohtsuka et al., J. Biol. Chem. 260: 2605-8, 1985; Rossolini et al., Mol. Cell. Probes 8: 91-8, 1994). The term nucleic acid can be used interchangeably with gene, cDNA, mRNA, oligonucleotide and polynucleotide.

[0123] "Polypeptide" is used in its conventional sense, i.e., as a sequence of amino acids. Polypeptides are not limited to products of a particular length. Peptides, polypeptides, and proteins are included within the definition of polypeptide, and unless expressly indicated otherwise, such terms may be used interchangeably herein. This term also includes post-expression modifications of the polypeptide, such as glycosylation, acetylation, phosphorylation, etc., and other modifications known in the art, both naturally occurring and non-naturally occurring. The polypeptide may be a complete protein or a subsequence thereof.

[0124] The term "identical" or "identity" percentage as known in the art refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between nucleic acid molecules or polypeptides (as the case may be), as determined by the match between strings of two or more nucleotide sequences or two or more amino acid sequences. "Identity" measures the percentage of identical matches between the smaller of two or more sequences with a gapped alignment (if any), the gap being addressed by a specific mathematical model or computer program (i.e., an "algorithm"). "Substantial identity" refers to a sequence having at least about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% sequence identity to a specified sequence. In some aspects, the identity is present in a region of at least about 50-100 amino acids or nucleotides in length. In other aspects, the identity is present in a region of at least about 100-200 amino acids or nucleotides in length. In other aspects, the identity is present in a region of at least about 200-500 amino acids or nucleotides in length. In certain aspects, percent sequence identity is determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, and Smith-Waterman algorithms.

[0125] The term "similarity" is a related concept, but compared to "identity", it refers to a measure of similarity including both identical matches and conservative substitution matches. If two polypeptide sequences have, for example, 10 / 20 identical amino acids, and the rest are non-conservative substitutions, then the identity and similarity percentages are both 50%. In the same example, if there are five positions with conservative substitutions, the identity percentage is still 50%, but the similarity percentage will be 75% (15 / 20). Therefore, in the presence of conservative substitutions, the similarity percentage between the two polypeptides will be higher than the identity percentage between the two polypeptides.

[0126] It should also be specifically understood that any numerical value listed herein includes all values ​​from the lower limit to the upper limit, that is, all possible combinations of numerical values ​​between the lowest and highest values ​​listed are considered to be explicitly stated in this application. For example, if a concentration range of about 1% to 50% is stated, it is expected that values ​​such as 2% to 40%, 10% to 30%, or 1% to 3% are explicitly listed in this specification. The values ​​listed above are only examples of specific expectations.

[0127] In various aspects, ranges are expressed herein as from "about" or "approximately" one particular value and / or to "about" or "approximately" another particular value. When values ​​are expressed as approximations by using the antecedent "about," it should be understood that a certain amount of variation is included in the range.

[0128] The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter or an array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

[0129] As used herein, the term "purified" or "substantially purified" as used herein refers to enrichment of the desired protein by at least 20%, more preferably at least 50%, even more preferably at least 75%, and most preferably at least 90% or even 95%.

[0130] Each publication, patent application, patent, and other reference cited herein is incorporated by reference in its entirety to the extent it is consistent with this disclosure.

[0131] The publications disclosed herein are provided only for their disclosures prior to the filing date of the present invention. Nothing herein should be construed as an admission that the present invention is not entitled to preempt such publications due to prior invention. In addition, the publication dates provided may be different from the actual publication dates, which may require independent confirmation.

[0132] Recitation of ranges of values ​​herein are merely intended to serve as a shorthand method of referring individually to each separate value and each endpoint falling within the range, unless otherwise indicated herein, and each separate value and endpoint is incorporated into the specification as if it were individually recited herein.

[0133] Unless otherwise indicated herein or clearly contradicted by context, all methods described herein are performed in any suitable order. With respect to any method provided, the steps of the method can be performed simultaneously or sequentially. When the steps of the method are performed sequentially, unless otherwise indicated, the steps can be performed in any order.

[0134] Where the method comprises a combination of steps, each and every combination or subcombination of steps is encompassed within the scope of the present disclosure unless otherwise indicated herein.

[0135] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0136] It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes based thereon will be apparent to those skilled in the art and should be included within the spirit and scope of this application and the scope of the appended claims.

[0137] VII. Examples

[0138] Example 1

[0139] This example describes the materials and methods used in the subsequent examples.

[0140] Materials and methods

[0141] Reconstruction of non-membrane protein channels

[0142] For non-membrane protein channels, it is difficult to directly insert them into lipid bilayers or polymer membranes because, unlike membrane protein channels, non-membrane protein channels usually lack a hydrophobic layer in the middle and hydrophilic layers at both ends, so extensive engineering is required. In order to be used for biosensing or sequencing, non-membrane protein channels also need to be engineered and functionalized using different probes. Although non-membrane protein channels may originate from various sources with different sequences, shapes, structures or properties, the strategies and methods used to reengineer them and enable them to be used as nanopores have some common features. As shown in Figures 1A and 1B, three different domains are important for membrane anchoring, and two regions are particularly important for the conjugation of functional modules for single-molecule sensing. In order to reengineer these different domains and change the hydrophobic or hydrophilic properties or functionalized conjugation sites or probes, a series of molecular cloning work is involved. Typically, general restriction enzyme cloning methods are used for various engineering purposes. However, other cloning methods, such as Recombinant cloning, Cloning, isothermal assembly reactions or IIS-type assembly.

[0143] Expression and purification of non-membrane proteins

[0144] Although non-membrane protein channels may originate from a variety of sources with different sequences, shapes, structures, or properties, the strategies and methods used to express and purify them share some common features.

[0145] First, the non-membrane protein channel gene of heavy engineering is cloned into an expression vector with or without a tag at the end. The vector is then transformed into a suitable protein expression host such as an Escherichia coli (E.coli) system. After the protein channel is expressed in the host, the host is cracked and a series of steps are taken to remove the host fragments. Finally, the non-membrane protein can be purified by one of the following methods or in combination, such as affinity chromatography, exchange chromatography, size exclusion chromatography or other purification methods commonly used.

[0146] For example, non-membrane protein channel genes and variant genes are cloned into a PET23a vector with a His tag at the N-terminus. After transformation into BL21 (DE3) cells, a BL21 (DE3) colony is inoculated in 5 mL of fresh LB medium in the presence of antibiotics and cultured in a shaker at 37 ° C for several hours until OD reaches 0.8. The flask is then kept at 4 ° C for cooling. Then 0.5 mM IPTG is added to the flask for induction. The bacteria are cultured overnight at 16 ° C in a shaker. The bacteria are harvested at 8000 rpm for 10 min, the supernatant is discarded, and the precipitate is then suspended with lysis buffer. The bacterial solution is sonicated until the solution becomes transparent and non-viscous. The solution is centrifuged at 12000 rpm for 30 min after sonication, the supernatant is discarded and the precipitate is collected. 10 ml of urea (8 M) is added to the precipitate and oscillated at a low speed on a shaker until the precipitate is completely dissolved in urea. The solution is centrifuged at 12000 rpm for 10 min. The supernatant was added to 100 ml of protein refolding buffer and stirred overnight. The solution was centrifuged at 12000 rpm for 30 min after refolding, the precipitate was discarded and the supernatant was collected. The supernatant was passed through a 0.45 um syringe filter to discard the denatured protein. The supernatant was added to a dialysis bag, and the dialysate was replaced three times. The liquid in the dialysis bag was collected and centrifuged at 12000 rpm for 10 minutes, the precipitate was discarded and the supernatant was collected. The nickel beads were balanced with lysis buffer, and the supernatant was added to the beads. The beads were then washed with wash buffer. The protein was eluted using 7 to 10 column volumes of elution buffer. The eluate was collected and concentrated to 5 mL. The eluate was centrifuged at 12000 rpm for 10 min, and then the supernatant was absorbed and injected into the AKTA FPLC with a syringe. Before injection, the sample loop was washed with 10 mL of lysis buffer. The protein was collected after passing through the size exclusion column. Run SDS-PAGE gel after SEC to examine protein samples and store at -80 °C.

[0147] Conjugation

[0148] In order to functionalize or enhance the hydrophobicity or hydrophilicity of non-membrane protein channels with different probes, various conjugation methods can be used. Although non-membrane protein channels may originate from various sources with different sequences, shapes, structures or properties, the strategies and methods for conjugation have some common features. In order to conjugate hydrophobic parts to non-membrane protein channels, reactions can be performed on cysteine ​​groups on protein channels. Each subunit of a protein channel contains one or more cysteines, which are located in the middle layer of the channel and are accessible to the environment. A protein solution was prepared in a pH 6.8 buffer containing 0.5M NaCl, 50mM Tris, and 15% glycerol. The solution was degassed, and a 100-fold excess of TCEP was added to the solution. After incubation at room temperature for 20min, 4 μL of 4mM cholesterol-PEG-maleimide was added dropwise to the protein solution, and the reaction mixture was incubated at room temperature in the dark for 2 hours. Excess cholesterol-PEG-maleimide was removed by a NanoSep 100K spin column. The labeling of the protein was checked with 12% SDS-PAGE.

[0149] In order to conjugate the probe to the non-membrane protein channel, click chemistry such as tetrazine-olefin connection or azide-alkyne click chemistry is used. For tetrazine-olefin connection, a protein solution is prepared in a pH 6.8 buffer containing 0.5M NaCl, 50mM Tris, 15% glycerol. The solution is degassed, and 100 times excess TCEP is added to the solution. After incubation for 20min, 1.6 μL of 10mM methyl tetrazine-PEG4-maleimide is added dropwise to the protein solution, and the mixture is incubated in the dark at room temperature for 1 hour. Excess methyl tetrazine-PEG4-maleimide is removed by desalting using a desalting spin column. 50 μL of probe solution is prepared in a pH 6.8 buffer containing 0.5M NaCl, 50mM Tris. The solution is degassed, and 100 times excess TCEP is added to the solution. After incubation for 20 min, 6 μL of 25 mM TCO-PEG3-maleimide was added dropwise to the oligomer solution, and the mixture was incubated at room temperature for 2 hours. Excess TCO-PEG3-maleimide was removed by desalting column. The labeling of the probe was verified by 20% urea-PAGE gel.

[0150] For azide-alkyne connection, TCO-modified probes were mixed with methyl tetrazine-labeled proteins at different molar ratios to achieve optimal protein labeling efficiency. The mixture was incubated at room temperature for 1 hour. Conjugation was verified with 12% SDS-PAGE. 40 μL of a 20 μM protein solution was prepared in a pH 6.8 buffer containing 0.5 M NaCl, 50 mM Tris, 15% glycerol. The solution was degassed and a 100-fold excess of TCEP was added to the solution. After incubation for 20 min, 1.6 μL of 10 mM sulfo DBCO-PEG4-maleimide was added dropwise to the protein solution, and the mixture was incubated at room temperature in the dark for 1 hour. Excess maleimide reagent was removed by desalting using a desalting spin column. DBCO-modified proteins were mixed with azide-modified probes at equimolar concentrations, and the reaction mixture was incubated at room temperature for 2 hours. Conjugation was verified with a 12% SDS-PAGE gel.

[0151] Nanopore experimental setup and data recording

[0152] Although non-membrane protein channels may be derived from various sources with different sequences, shapes, structures or characteristics, all non-membrane protein channels or variants can be applied to similar nanopore settings or devices. Generally, a sensor chip or array with one or more orifices is provided. The sensor chip can support the formation of a lipid membrane or polymer membrane, so that the compartment can be divided into a cis (top) and a trans (bottom) compartment. Both compartments are filled with a conductive buffer. The input electrode is embedded in one compartment, and the ground electrode is embedded in another compartment. In addition, the setting can also be combined with a fluid system to enable a sample to flow from a container to the sensor device. In order to insert a non-membrane protein channel into a lipid membrane or a polymer membrane, the protein channel is suspended in its corresponding storage buffer, diluted 50-100 times in a conductive buffer (usually 1M KCl or 1M NaCl, 5mM HEPES or Tris, pH 7.6), and added to the top compartment. Under an applied potential (constant holding voltage or ramp voltage) and with or without detergent, it can be observed that the protein channel is directly inserted into the planar membrane. When no analyte is present, the current is stable and flat. When analyte is present, interaction with the probe results in a change in the recorded current.

[0153] Data analysis

[0154] Although non-membrane protein channels may originate from a variety of sources with different sequences, shapes, structures, or properties, the strategies and methods used for data analysis share some common features. Typically, about 10,000+ current blockade events (translocation or single-molecule binding events) are analyzed to ensure that the results are within statistical significance. Custom algorithms based on MATLAB or PYTHON are developed for quantitative and rapid processing of events. Typically, two parameters are used: (1) the current blockade fraction, expressed as [(current 未阻断 -Current 分析物阻断之后 ) / Current 未阻断 ]; and (2) residence time: τ 中断 (duration of the event) and τ 连通 (the time between consecutive events). According to τ 连通 and τ 中断 , we can obtain κ 缔合 (association rate constant) and κ 解离 (dissociation rate constant), and finally obtain K d (equilibrium dissociation constant). A calibration curve is constructed to show that the capture rate varies with the analyte concentration. After an unknown concentration of analyte is introduced into the nanopore, the average capture rate can be calculated and the analyte concentration can be determined from the calibration curve. Analysis of clinical samples requires further tuning of the analysis algorithm to clearly distinguish "contamination" or nonspecific signals from true analyte-induced events. In order to standardize the analyte detection system, an "endogenous" normalizer with a "spiked" control is typically used. The platform data is then cross-validated using standard assays commonly used in the diagnostic field, such as immunoassays and qRT-PCR. Finally, the statistical sample size / power analysis is based on a two-sample t-test for comparison of the two groups, and a two-way analysis of variance (ANOVA) for a combination of the two factors.

[0155] Example 2

[0156] Expression and purification of phi29 gp-9 tail protein

[0157] Purified phi29 gp-9 tail protein and its variants in SDS PAGE Figure 3 to Figure 4Shown in . Expression and purification steps are as follows. The phi29 gp-9 tail protein gene and variant gene are cloned into the vector pBDHT with a His tag at the N-terminus. After transformation into BL21 (DE3), a BL21 colony is inoculated in 5mL fresh LB medium with antibiotics inside, and cultured in a shaker (220rpm) at 37°C for several hours until OD reaches 0.8. The flask is then kept at 4°C for cooling. Then 0.5mM IPTG is added to the flask for induction. The bacteria are cultured overnight at 16°C in a shaker (180rpm). The bacteria are harvested at 8000rpm for 10min, the supernatant is discarded, and the precipitate is then resuspended in lysis buffer (50mM Tris pH 8.0, 500mM NaCl). The bacterial solution is ultrasonically treated until the solution becomes transparent and non-viscous. The solution is centrifuged at 12000rpm for 30min after ultrasonic treatment, the supernatant is discarded and the precipitate is collected. 10ml urea (8M) is added to the precipitate and oscillated at a low speed on an oscillator until the precipitate is completely dissolved in urea. The solution is centrifuged at 12000rpm for 10min. The supernatant is added to 100ml protein renaturation buffer (15% glycerol, 500mMNaCl, 50mM Tris, 2M L-arginine, pH 8.0) and stirred overnight. The solution is centrifuged at 12000rpm for 30min after refolding, the precipitate is discarded and the supernatant is collected. The supernatant is passed through a 0.45um syringe filter to discard the denatured protein. The supernatant is added to a dialysis bag, and the dialysate (50mM NaCl, 5mM Tris) is changed three times. The liquid in the dialysis bag is collected and centrifuged at 12000rpm for 10 minutes, the precipitate is discarded and the supernatant is collected. Nickel beads were balanced with lysis buffer, and supernatant was added to beads. Wash beads with 50 column volumes of wash buffer (50mM Tris pH 8.0, 500mM NaCl, 25mM imidazole). Eluted protein was washed with 7-10 column volumes of elution buffer (50mM Tris pH 8.0, 500mM NaCl, 500mM imidazole). Eluate was collected and concentrated to 5mL. Eluate was centrifuged at 12000rpm for 10min, and then supernatant was absorbed and injected into AKTA FPLC with a syringe. Before injection, sample loop was washed with 10mL lysis buffer. Protein was collected after passing through a size exclusion column. SDS-PAGE gel was run after SEC to check protein samples, and stored at -80°C.

[0158] Example 3

[0159] Bacteriophage tail proteins as nanopores

[0160] Many phages contain long contractile or non-contractile tails or short non-contractile tails. The tail plays a key role in host cell recognition, membrane penetration and viral genome ejection. Tail proteins are derived from (including but not limited to) phi29, T4, T3, T5, T7, SPP1, P22, P2, P3, λ, μ, HK97 and C1.

[0161] These protein channels of the present invention are ideal for biosensing and sequencing of biomolecules such as disease-related biomarkers, polynucleotides and polypeptide sequences. With improved membrane capacity, the modified protein channels can be effectively inserted into lipid membranes or polymer membranes and act as nanopores for biosensing and sequencing. By conjugating with various probes, the modified protein channels have the ability to detect biomarkers associated with specific diseases with high sensitivity and specificity. The pores of the present invention can be present in homologous or heterologous pores.

[0162] Representative Example: Gp-9 tail protein from phi29

[0163] The crystal structure of the phi29 phage tail (gp9) shows that the six gp9 subunits form a hexameric or cylindrical tube structure. Inside the structure, the distal end is blocked by six flexible hydrophobic loops before triggering DNA ejection. In order to deliver genomic dsDNA to the cytoplasm of the host cell, the phi29 tail needs to penetrate the cell membrane. The length of the tube is about 12.5nm. The tube has an inner diameter of about 4nm and an outer diameter of about 9nm. The tube wall is mainly composed of β-pleated sheets with a thickness of about 2.5nm.

[0164] A full-length gp9 clone and a series of mutants were constructed ( Figures 2 to 6), such as gp9Δloop[417-491], in which the disordered region (residues 417-491) is missing. According to the crystal structure, the gp9Δ417-491 structure is also a cylindrical tubular homohexamer. By studying the structure of the tail protein, amino acids 130-170, 300-325, 350-390, 530-595 are located on the surface of the middle channel, where they can interact with the hydrophobic layer of the membrane. Therefore, the attachment of hydrophobic groups to these sites or the mutation of these amino acids to hydrophobic amino acids can change the membrane insertion ability of the channel, and the hydrophilic amino acids include glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), proline (Pro), phenylalanine (Phe), methionine (Met) and tryptophan (Trp). Specifically, mutations at one or any combination of the following sites are critical: K134I, D138L, D139L, D158L, E163V, E309V, D311V, K321V, K356A, K358A, D377A, D381V, N388L, R524I, R539A, E595V. In order to conjugate the hydrophobic group to the middle of the channel, it is important to mutate the following sites to cysteine: E595C, K321C, and K358C. In addition, amino acids 250-300 and 20-50 are located on the surface of the upper and lower parts of the channel, where they can interact with the hydrophilic environment.

[0165] Viral portal proteins as nanopores

[0166] Portal proteins are not only present in bacteriophages phi29, T3, T4, T5, T7, SPP1 and P22, but also in other viral systems, such as adenovirus and herpes virus. The portal channel, known as the connector, is a pore-like protein structure with a central channel that serves as a pathway for genomic DNA to enter the viral capsid during packaging and leave during infection. Although structural studies indicate that there are significant differences in sequence homology and size between different viral connector proteins, they are all similar in topology, having a truncated cone shape. The stoichiometry of the connector derived from overexpressed proteins usually varies depending on the expression conditions. If these protein channels of the present invention can be directly inserted into a solid polymer membrane, the protein channels may be ideal for biosensing and sequencing applications. Since the structures of the connectors from different viral portal proteins show similar features, the principles outlined above are also applicable to all of them by extension.

[0167] Representative Example: P22 Portal Channel

[0168] P22 is a tailed phage that assembles an empty precursor capsid, which is then packaged with viral DNA by a powerful packaging motor. The P22 portal protein forms a channel-like structure for bidirectional passage of viral DNA. The Podoviridae family of short-tailed dsDNA phages includes members of the P22-like subgroup, such as Sf6, CUS-3, ε34, and APSE-1. The portal barrel structure is highly dynamic and prone to proteolysis in solution. The P22 portal protein is composed of 12 identical subunits, which are symmetrically arranged around the central channel. The total height is about 30nm, with a funnel-shaped core with a diameter of about 17nm, which is connected to an alpha helical tube about 20nm long. In the entire structure, the average inner diameter of the channel varies between 3.5nm and 7.5nm.

[0169] A series of mutants were constructed (Figures 7 to Fig.11), which includes the following defining features: (1) The portal core (residues 1-602) is topologically similar to other viral protein channels, but the presence of the helical barrel structure tube is unique to P22. The connection between the portal core and the helical barrel structure can be easily cleaved by chymotrypsin in solution, indicating that the two domains are flexible in nature. The present invention includes removal of barrel structure residues 603-725 and replacement with any peptide or nucleic acid sequence as a separate recognition domain. (2) The present invention includes changes (deletions, truncations, mutations) of internal flexible loop residues 464-492 to alter electrophysiological properties and / or detection capabilities. (3) The present invention includes the use of EDTA (60mM or higher) to assemble the dodecameric complex: for the correct assembly of the dodecameric ring, non-specific capture of chelated divalent cations at the monomer-monomer interface is essential. (4) The present invention involves changing the overall electronegativity of the interior of the channel by altering the five loops of residue Glu70 (which is clustered together with Glu423, Glu414, Glu406, Glu393, and Glu396). (5) The present invention includes changing any hydrophobic amino acid (Phe 24, Ile25, Leu28, Phe60, Phe128, Pro129 and Pro132) that forms a band below the wing domain to change the hydrophobicity of the surface; (6) The present invention includes adding several amino acids (any natural or unnatural amino acids) at the end with the purpose of using these amino acids as anchor points (such as cysteine ​​or lysine or arginine) for increasing functionality or changing electrophysiological properties for membrane insertion and channel stability (hydrophilic or hydrophobic tags); (7) The present invention includes mutagenesis of the hydrophobic layer and the hydrophilic layer; middle: amino acids 250 to 300, 10-45; upper part: 450-500; lower part: 350-380; mutation of Arg476 or C-terminal to Cys for conjugation; middle THR240, VAL244, Arg 273, for Cys mutagenesis for conjugation of cholesterol.

[0170] Representative Example: T4 Portal Channel

[0171] The T4 portal exists mainly as a 12-mer (some are 11-mer or 13-mer depending on protein expression conditions) ring, 14 nm long, 7 nm wide, and an internal channel diameter of 3 nm. Since the channel is assembled from 12 subunits, changing one or more residues in one monomer will trigger an effect in the entire channel, and the mutations exist in the same plane of the molecule. The present invention includes ( Figure 12 to Figure 14 and Fig.16): (1) changing the overall electronegativity of the channel interior by changing the ring of charged residues; (2) changing the two basic residues R338 and K342 at the entrance of the internal channel (using any amino acid to change the hydrophilicity); (3) adding several amino acids (any natural or unnatural amino acids) at the termini with the purpose of using these amino acids as anchor points (such as cysteine ​​or lysine or arginine) for increasing functionality or changing the electrophysiological properties (hydrophilic or hydrophobic tags) for membrane insertion and channel stability; and (5) changing (deleting, truncating, mutating) the internal flexible loop residues 374-398 to change the electrophysiological properties and / or detection capabilities.

[0172] Example 4

[0173] Nanoporous shell membrane composition

[0174] Planar bilayer lipid membranes (BLM) or polymer membranes were produced in (a) BCH-1A horizontal BLM cells (Eastern Scientific) or (b) homemade custom chambers. Teflon partitions with 100 or 200 μm orifices were placed in the device to divide the BLM cell into cis (top) and trans (bottom) compartments. The homemade chambers had pre-drilled orifices of 100 or 200 μm to separate the cis compartment from the trans compartment.

[0175] Lipid membrane: Planar lipid bilayers of varying composition were formed by pre-coating the orifice with lipids in hexane (concentration: 0.5 mg / ml) followed by coating with lipids in n-decane (concentration: 20-30 mg / ml). Examples of lipid compositions include: (i) zwitterionic lipids such as 100% DPhPC or DOPC or POPC; (ii) 0%-50% anionic lipids such as DPhPG / DOPG / POPG or DPhPS / DOPS / POPS, mixed with composition (i) in proportions (the final proportions totaling 100%); (iii) 0%-25% cholesterol, mixed with compositions (i) and (ii) in proportions. The exact lipid composition depends on the properties of the protein. Typical lipid membrane compositions used include: 100% DPhPC; 100% DPhPC; 30% DPhPS; 70% DPhPC:28% DPhPG:2% cholesterol.

[0176] Polymer films: Planar polymer films of varying composition were formed by hand coating using films suspended in organic solvents such as decane or silicone oil (based on polyphenyl-methylsiloxane, or based on polydimethylsiloxane with a viscosity of 20 mPa.s). The film compositions were triblock copolymers based on polyoxazolines (Figure 17), such as:

[0177] (i) PEOXA-PEO-PEOXA [poly(2-ethyloxazoline)-b-poly(ethylene oxide)-b-poly(2-ethyloxazoline)

[0178] Oxazoline)]PEOXA-PEO-PEOXA;

[0179] (ii) PMOXA-PDMS-PMOXA [poly(2-methyloxazoline)-b-poly(dimethylsiloxane)-b-poly(2-methyloxazoline)]; (with ethyl-benzyl or propyl or propyl-ethoxy linkages between blocks)

[0180] (iii) PMOXA-PB-PMOXA [poly(2-methyloxazoline)-b-poly(1,4-butadiene)-b-poly(2-methyloxazoline)

[0181] oxazoline)];

[0182] (iv) PMOXA-PE-PMOXA [poly(2-methyloxazoline)-b-poly(ethylene)-b-poly(2-methyloxazoline)]

[0183] oxazoline)];

[0184] (v) PMOXA-PEO-PMOXA [poly(2-methyloxazoline)-b-poly(ethylene oxide)-b-poly(2-methyloxazoline)]

[0185] Typical membranes used include PMOXA6-PDMS35-PMOXA6; PMOXA6-PDMS65-PMOXA6; PMOXA11-PDMS65-PMOXA11; PMOXA5-PDMS13-PMOXA5; PMOXA3-PDMS38-PMOXA3 (Figure 17). The block length (indicated by the subscripts X and Y in PMOXAX-PDMSY-PMO XAX), which determines the length of the hydrophilic or hydrophobic block, can be tuned according to the following factors: (1) a certain membrane thickness is required for stable insertion into protein pores; (2) the membrane needs to maintain very low permeability; (3) the membrane must be mechanically and chemically stable under different solution conditions (including extreme pH (1-12) and high / low salt environments) for extended periods of time.

[0186] Example 5

[0187] Insertion of protein channels into membranes

[0188] Typically, protein channels (tail proteins or portal channels) suspended in their corresponding storage buffer are diluted 50-100 times in a conductive buffer (usually 1M KCl or 1M NaCl, 5mM HEPES or Tris, pH 7.6) and added to the top compartment of the BLM cell. Under an applied potential (either a constant holding voltage or a ramping voltage), the protein channels can be observed to insert directly into the planar membrane ( Figure 6 , Fig.11 , Fig.14 , Fig.16 and Fig.19 ).

[0189] If desired, the membrane compositions can also be used to generate vesicular polymersome structures with varying polydispersities to reconstruct protein channels. For high insertion efficiency, varying amounts of glycerol, CsCl and / or sucrose can be encapsulated within the polymersomes. The resulting protein-polymersomes can then fuse with planar bilayers of the same composition in a salt- and voltage-dependent manner.

[0190] Example 6

[0191] Conjugation of hydrophobic moieties to non-membrane protein channels via reaction with cysteine ​​residues

[0192] Here, the T4 gp20 portal protein is used as an example to illustrate how hydrophobic moieties can be conjugated to non-membrane channels via reaction with cysteine ​​residues. Each subunit of the protein channel contains three cysteines, which are located in the middle layer of the channel and are accessible to the environment ( Fig.13 ). 40 μL of a 20 μM protein solution was prepared in a pH 6.8 buffer containing 0.5 M NaCl, 50 mM Tris, 15% glycerol. The solution was degassed, and a 100-fold excess of TCEP was added to the solution. After incubation at room temperature for 20 min, 4 μL of 4 mM cholesterol-PEG-maleimide was added dropwise to the protein solution, and the reaction mixture was incubated at room temperature in the dark for 2 hours. Excess cholesterol-PEG-maleimide was removed by a NanoSep 100K spin column. The labeling of the protein was checked by 12% SDS-PAGE ( Fig.13 ).

[0193] Example 7

[0194] Insertion of non-membrane protein channels carrying hydrophobic moieties into lipid or polymer membranes

[0195] Planar polymer membranes were produced. Direct insertion of non-membrane protein channels carrying hydrophobic moieties was observed after adding protein channels to the cis chamber under an applied voltage (either constant holding voltage or ramping voltage). Fig.14). Mutation to hydrophobic amino acids or conjugation of hydrophobic groups to the middle layer of the phi29gp-9 ​​tail protein can significantly enhance the insertion process and its stability.

[0196] Example 8

[0197] Conjugation of probes to non-membrane protein channels via click reactions

[0198] The phi29 gp10 portal protein was used as a representative example.

[0199] Strategy 1: via tetrazine-olefin connection: 40 μL of 20 μM protein solution was prepared in pH 6.8 buffer containing 0.5M NaCl, 50mM Tris, 15% glycerol. The solution was degassed and 100-fold excess TCEP was added to the solution. After incubation for 20 min, 1.6 μL of 10mM methyl tetrazine-PEG4-maleimide was added dropwise to the protein solution, and the mixture was incubated in the dark for 1 hour at room temperature. Excess methyl tetrazine-PEG4-maleimide was removed by desalting using a desalting spin column. 50 μL of 30 μM thiol-modified miRNA probe solution was prepared in pH 6.8 buffer containing 0.5M NaCl, 50mM Tris. The solution was degassed and 100-fold excess TCEP was added to the solution. After incubation for 20 min, 6 μL of 25 mM TCO-PEG3-maleimide was added dropwise to the oligomer solution, and the mixture was incubated at room temperature for 2 hours. Excess TCO-PEG3-maleimide was removed by a desalting column. The labeling of the miRNA probe was verified by 20% urea-PAGE gel. In order to conjugate the miRNA probe to the protein, the TCO-modified miRNA probe was mixed with methyl tetrazine-labeled protein at different molar ratios to achieve optimal protein labeling efficiency. The mixture was incubated at room temperature for 1 hour. Conjugation was verified by 12% SDS-PAGE.

[0200] Strategy 2: via azide-alkyne click chemistry: 40 μL of a 20 μM protein solution was prepared in a pH 6.8 buffer containing 0.5 M NaCl, 50 mM Tris, 15% glycerol. The solution was degassed and a 100-fold excess of TCEP was added to the solution. After incubation for 20 min, 1.6 μL of 10 mM sulfo DBCO-PEG4-maleimide was added dropwise to the protein solution, and the mixture was incubated at room temperature in the dark for 1 hour. Excess maleimide reagent was removed by desalting using a desalting spin column. The DBCO-modified protein was mixed with an azide-modified miRNA probe at equimolar concentrations, and the reaction mixture was incubated at room temperature for 2 hours. Conjugation was verified with 12% SDS-PAGE.

[0201] Example 9

[0202] Validation of DNA probes conjugated to proteins

[0203] The protein-miRNA probe conjugate was incubated with the target miRNA oligomer at equimolar concentration for 30 min at room temperature. The binding of the protein-miRNA probe to the target miRNA was verified by 12% SDS-PAGE ( Fig.15 ).

[0204] Example 10

[0205] PSA detection using engineered non-membrane protein channels

[0206] To conjugate protein probes to nanopore channels, various approaches have been tried and tested, including reaction of cysteine ​​residues with methyltetrazine-PEG4-maleimide and subsequent reaction with TCO-labeled probes, and SpyCatcher / Spytag protein conjugation systems. It is shown how a single-chain antibody against PSA is conjugated to the phi29 gp10 portal protein channel via SpyCatcher / Spytag. Construction and purification of a Phi29 gp10 protein channel with a C-terminal SpyTag peptide. Construction and purification of a single-chain antibody against PSA with a C-terminal SpyCatcher. Verification of the assembled protein channel-PSA single-chain antibody by gel Fig.18 ). Purified assembled protein channel-PSA single-chain antibody was then inserted into the polymer membrane to test its ability to bind PSA antigen. The procedure for setting up the electrophysiological experiments was previously described. After insertion, a series of different concentrations of PSA antigen were added to the chamber and unique binding events were observed ( Fig.19 ).

[0207] Embodiment 11

[0208] MicroRNA detection using engineered non-membrane protein channels

[0209] To conjugate nucleic acid probes to nanopore channels, various different approaches have been tried and tested, as outlined in Example 6. It has been demonstrated that miR-21 probes can be conjugated to the T4 gp20 portal protein channel. The purified conjugated complexes were inserted into polymer membranes to test their ability to bind to the corresponding microRNAs. The procedure for setting up electrophysiological experiments was previously described. After insertion, a series of different concentrations of microRNAs were added to the chamber and unique binding events were observed ( Fig.16 ).

[0210] Through the following detailed description, other objects, features and advantages of the present invention will become clear. However, it should be understood that the detailed description and examples, although indicating specific embodiments of the present invention, are given only by way of illustration. In addition, it is contemplated that changes and modifications within the spirit and scope of the present invention will become clear to those skilled in the art based on this detailed description.

[0211] Specifically, the present invention includes but is not limited to the following:

[0212] 1. A nanopore assembly for detecting an analyte, the nanopore assembly comprising a channel formed by a plurality of subunits, wherein each of the subunits comprises a non-membrane protein capable of forming a protein channel.

[0213] 2. A nanopore assembly according to item 1, wherein each of the subunits comprises a polypeptide having a polypeptide sequence that is at least 75% identical to a polypeptide sequence selected from SEQ ID NOs: 1-35.

[0214] 3. A nanopore assembly according to item 1 or 2, wherein the polypeptide comprises at least one residue substituted with cysteine.

[0215] 4. A nanopore assembly according to any one of the preceding items, wherein the polypeptide comprises a polypeptide sequence that is at least 75% identical to SEQ ID NO: 4-12.

[0216] 5. A nanopore assembly according to any one of the preceding items, further comprising a probe for detecting an analyte, said probe being operably linked to at least one of said subunits.

[0217] 6. A nanopore assembly according to item 5, wherein the probe is selected from the group consisting of chemicals, carbohydrates, aptamers, nucleic acids, peptides, proteins, antibodies and receptors.

[0218] 7. A nanopore assembly according to item 5, wherein the probe comprises a sequence that is at least 75% identical to a sequence selected from SEQ ID NOs: 36-79.

[0219] 8. A nanopore assembly according to item 5, wherein the probe is an anti-PSA antibody.

[0220] 9. A nanopore assembly according to item 5, wherein the analyte is selected from nucleic acids, amino acids, peptides, proteins, polymers and chemical molecules.

[0221] 10. A nanopore assembly according to claim 5, wherein the analyte is selected from PSA, CEA, AFP, VCAM, MiR-155, MiR-22, MiR-7, MiR-92a, MiR-122, MiR-192, MiR-223, MiR-26a, MiR-27a and MiR-802.

[0222] 11. A nanopore assembly according to item 5, wherein the analyte is PSA or a fragment thereof.

[0223] 12. A nanopore assembly according to any one of items 5-9, wherein the probe is operably linked to at least one of the subunits via a covalent bond.

[0224] 13. A nanopore assembly according to claim 12, wherein the covalent bond comprises a disulfide bond, an ester bond or a thiol bond.

[0225] 14. A nanopore assembly according to any one of items 5-13, wherein the probe is operably connected to a position close to the entrance of the channel.

[0226] 15. A nanopore assembly according to any one of items 5-13, wherein the probe is operably connected to a location inside the channel.

[0227] 16. A nanopore assembly according to any of the preceding items, wherein the channel is embedded in a polymer vesicle.

[0228] 17. A nanopore assembly according to any of the preceding items, further comprising a membrane, wherein the channel is inserted into the membrane.

[0229] 18. A nanopore assembly according to item 17, wherein the membrane comprises a polymer membrane or a lipid membrane.

[0230] 19. A nanopore assembly according to item 18, wherein the polymer membrane comprises an alternating copolymer, a periodic copolymer, a block copolymer, a diblock copolymer, a triblock copolymer, a terpolymer or a combination thereof.

[0231] 20. A nanopore assembly according to claim 19, wherein the polymer membrane comprises PMOXA-PDMS-PMOXA.

[0232] 21. A nanopore assembly according to any one of items 17-20, further comprising at least one of cholesterol and porphyrin.

[0233] 22. A device for detecting an analyte, the device comprising a nanopore assembly according to any of the preceding items and optionally a support for the nanopore assembly.

[0234] 23. A kit comprising a nanopore assembly according to any one of items 1 to 21 and optionally instructions for using the nanopore assembly.

[0235] 24. A method for detecting an analyte, the method comprising:

[0236] (a) contacting a sample containing an analyte with a nanopore assembly according to any one of items 1 to 21;

[0237] (b) applying an electric current across a channel of the nanopore assembly;

[0238] (c) determining the current through the channel at one or more time intervals; and

[0239] (d) comparing the current measured at one or more time intervals to a reference current, wherein a change in the current relative to the reference current is indicative of the presence of the analyte in the sample.

[0240] 25. A method according to claim 24, wherein the reference current is measured using a sample that does not contain the analyte.

[0241] 26. A method according to item 24 or 25, wherein the nanopore assembly is placed on a support.

Claims

1. A nanopore assembly for detecting an analyte, the nanopore assembly comprising a channel formed by a plurality of subunits, wherein each of the subunits comprises a non-membrane protein capable of forming a protein channel.

2. The nanopore assembly of claim 1, wherein each of the subunits comprises a polypeptide having a polypeptide sequence that is at least 75% identical to a polypeptide sequence selected from SEQ ID NOs: 1-35.

3. The nanopore assembly of claim 1 or 2, wherein the polypeptide comprises at least one residue substituted with cysteine.

4. The nanopore assembly of any one of the preceding claims, wherein the polypeptide comprises a polypeptide sequence that is at least 75% identical to SEQ ID NO: 4-12.

5. A nanopore assembly according to any one of the preceding claims, further comprising a probe for detecting an analyte, the probe being operably linked to at least one of the subunits.

6. The nanopore assembly of claim 5, wherein the probe is selected from the group consisting of a chemical, a carbohydrate, an aptamer, a nucleic acid, a peptide, a protein, an antibody, and a receptor.

7. The nanopore assembly of claim 5, wherein the probe comprises a sequence that is at least 75% identical to a sequence selected from SEQ ID NOs: 36-79.

8. The nanopore assembly of claim 5, wherein the probe is an anti-PSA antibody.

9. The nanopore assembly of claim 5, wherein the analyte is selected from the group consisting of nucleic acids, amino acids, peptides, proteins, polymers, and chemical molecules.

10. The nanopore assembly of claim 5, wherein the analyte is selected from the group consisting of PSA, CEA, AFP, VCAM, MiR-155, MiR-22, MiR-7, MiR-92a, MiR-122, MiR-192, MiR-223, MiR-26a, MiR-27a, and MiR-802.

Citation Information

Patent Citations

  • Base-detecting pore

    CN102144037A

  • Aptamer method

    CN104220874A

  • Nanopore-based analysis of protein characteristics

    CN106133513A

  • Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides

    HK1042501A

  • Lipid bilayer-integrated SPP1 connector protein nanopore and SPP1 connector protein variants for use as lipid bilayer-integrated nanopore

    US20170343530A1